XLO Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Xilio Therapeutics Inc | Needs refresh | Last updated: 2026-04-23T10:26:17Z

TickerXLO

Market Cap49.7M

Cash RunwayRunway > 12 months

Next Catalyst2027-02

Public Research Snapshot

Xilio Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for XTX202 in Advanced Solid Tumor (Phase 1 | Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
XTX202	Advanced Solid Tumor	n/a	Phase 1 \| Phase 2	Public pipeline row
XTX301	Advanced Solid Tumor	n/a	Phase 1 \| Phase 2	Public pipeline row
vilastobart (XTX101)	Advanced Solid Tumor	n/a	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-02	XTX301	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05052268	Phase 1 \| Phase 2	COMPLETED	95	2025-03-22
NCT04896697	Phase 1 \| Phase 2	RECRUITING	136	2026-03-30
NCT05684965	Phase 1 \| Phase 2	RECRUITING	358	2027-02

Scientific Context

clinical_stage | Phase 1
clinical_stage | Phase 1
conditions | Advanced Solid Tumor
conditions | Advanced Solid Tumor
conditions | Advanced Solid Tumor

Want the full XLO research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.